Ultragenyx Pharmaceutical | RARE - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Immunic USD 23.33M 2.67M 2025-12
Insmed USD 513.55M 109.86M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Kyowa Hakko Kirin JPY 109.02B 16.08B 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Moderna USD 1.78B 242M 2026-03
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03
Xoma USD 22.84M 1.67M 2024-09